Business Description
Onconetix Inc
NAICS : 541713
SIC : 2834
ISIN : US09610B1089
Description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.3 | |||||
| Debt-to-EBITDA | -0.2 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -4.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -144.5 | |||||
| 3-Year EPS without NRI Growth Rate | -96.2 | |||||
| 3-Year FCF Growth Rate | -71.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 11.35 | |||||
| 9-Day RSI | 19.42 | |||||
| 14-Day RSI | 27.67 | |||||
| 6-1 Month Momentum % | -42.21 | |||||
| 12-1 Month Momentum % | -58.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.06 | |||||
| Quick Ratio | 0.05 | |||||
| Cash Ratio | 0.02 | |||||
| Days Inventory | 69.04 | |||||
| Days Sales Outstanding | 32.79 | |||||
| Days Payable | 561.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.5 | |||||
| Shareholder Yield % | 13.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -39.14 | |||||
| Operating Margin % | -840.64 | |||||
| Net Margin % | -2759.57 | |||||
| FCF Margin % | -744.44 | |||||
| ROA % | -82.75 | |||||
| ROIC % | -22.1 | |||||
| ROC (Joel Greenblatt) % | -29097 | |||||
| ROCE % | -115.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.11 | |||||
| PB Ratio | 0.08 | |||||
| EV-to-EBIT | -0.39 | |||||
| EV-to-EBITDA | -0.4 | |||||
| EV-to-Revenue | 10.58 | |||||
| EV-to-FCF | -1.42 | |||||
| Earnings Yield (Greenblatt) % | -256.41 | |||||
| FCF Yield % | -493.48 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Onconetix Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.719 | ||
| EPS (TTM) (€) | -91.58 | ||
| Beta | 0 | ||
| Volatility % | 126.6 | ||
| 14-Day RSI | 27.67 | ||
| 14-Day ATR (€) | 0.00227 | ||
| 20-Day SMA (€) | 2.82 | ||
| 12-1 Month Momentum % | -58.33 | ||
| 52-Week Range (€) | 2.74 - 10.656 | ||
| Shares Outstanding (Mil) | 8.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Onconetix Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Onconetix Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Onconetix Inc Frequently Asked Questions
What is Onconetix Inc(FRA:J4T0)'s stock price today?
The current price of FRA:J4T0 is €2.82. The 52 week high of FRA:J4T0 is €10.66 and 52 week low is €2.74.
When is next earnings date of Onconetix Inc(FRA:J4T0)?
The next earnings date of Onconetix Inc(FRA:J4T0) is 2025-03-10 Est..
Does Onconetix Inc(FRA:J4T0) pay dividends? If so, how much?
Onconetix Inc(FRA:J4T0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers